Cellectis has signed a pharma partnering collaboration agreement with Servier to develop and commercialize novel product candidates targeting leukemia and solid tumors for $150 million.
The partnership covers the development and potentially the commercialization of Cellectis’ lead product candidate, UCART19.
Engineered allogeneic CD19 T-cells currently stand out as a real therapeutic innovation for treating various types of leukemias and lymphomas.
The agreement also included research, development, and potentially the commercialization of five other product candidates targeting solid tumors.
Cellectis will be responsible for the R&D of certain product candidates through the end of Phase I.
Servier may exercise an exclusive worldwide option for a license on each product candidate developed under the agreement.
Upon exercising each option, Servier will be responsible for taking over clinical development, registration and commercialization of each product.
The financial terms of the collaboration include an upfront payment of $10 million and up to $140 million for each of the six product candidates potentially developed, spread over various milestones in the development and commercialization phases.
In addition, Cellectis will receive royalties on the sales of commercialized products.
For further deal information visit Current Agreements (subscription required)
Report: Leukemia Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity